Additional Proxy Soliciting Materials (definitive) (defa14a)
December 04 2017 - 7:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2017
MELINTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-35405
|
|
45-4440364
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
300 George Street, Suite 301, New Haven, CT
|
|
06511
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (312)
767-0291
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☒
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01. Other Events.
On November 29, 2017, Melinta Therapeutics, Inc. (
Melinta
) announced that it had entered into a definitive agreement to acquire the
capital stock of certain subsidiaries and certain other assets related to the infectious disease business of The Medicines Company. Melinta held an investor conference call on November 29, 2017 to discuss the execution of the definitive
agreement.
A transcript of the conference call is attached as Exhibit 99.1 and is incorporated by reference herein.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this communication constitute forward-looking statements within the meaning of Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act and are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may,
plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking
statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions,
expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.
Risks and uncertainties for Melinta include, but are not limited to: inability to complete the proposed transactions; liquidity and trading market for shares
prior to and following the consummation of the proposed transactions; costs and potential litigation associated with the proposed transactions; failure or delay in obtaining required approvals by governmental or quasi-governmental entity necessary
to consummate the proposed transactions; failure to satisfy other conditions to the closing of the proposed transactions; risks related to the costs, timing and regulatory review of the Companys studies and clinical trials, including its
ability to address the issues identified by the FDA in the complete response letter relating to Melintas new drug applications for solithromycin for community acquired bacterial pneumonia; uncertainties in obtaining successful clinical results
for product candidates and unexpected costs that may result therefrom; inability or the delay in obtaining required regulatory approvals for product candidates, which may result in unexpected cost expenditures; failure to realize any value of
certain product candidates developed and being developed, in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products;
inability to commercialize and launch any product candidate that receives regulatory approval, including Baxdela; the Companys anticipated capital expenditures, its estimates regarding its capital requirements and its need for future capital;
uncertainties of cash flows and inability to meet working capital needs; cost reductions that may not result in anticipated level of cost savings or cost reductions prior to or after the consummation of the proposed transactions; the approval by the
FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for the Companys products may not be as large as
expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale manufacturing capabilities; loss of or diminished demand from one or more key customers or distributors; unexpected cost increases and pricing pressures; the possibility of economic recession
and its negative impact on customers, vendors or suppliers; and risks associated with the possible failure to realize certain benefits of the proposed transactions, including future financial, tax, accounting treatment, and operating results. Many
of these factors that will determine actual results are beyond Melintas ability to control or predict.
Other risks and uncertainties are more fully described in our Annual Report on Form
10-K
for the year ended December 31, 2016, as amended by Form
10-K/A,
filed with the SEC on April 13, 2017, and in other filings that Melinta makes and will make
with the SEC in connection with the proposed transactions, including the proxy statement described below under Important Information and Where to Find It. Existing and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. The statements made in this press release or presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and
beliefs to change. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as
required by law. These forward-looking statements should not be relied upon as representing our views as of any date after the date stated herein.
Participants in this Solicitation
Melinta and certain of
its directors and executive officers may be deemed to be participants in the solicitation of proxies from Melintas stockholders in connection with the proposed transactions. Additional information regarding persons who may, under the rules of
the SEC, be deemed to be participants in the solicitation of Melinta stockholders in connection with the proposed transactions, and a description of their direct and indirect interest, whether as security holders, directors or employees of Melinta
or otherwise, which may be different from those of Melintas stockholders generally, will be set forth in the definitive proxy statement filed with the SEC in connection with the proposed transactions. You can find information about
Melintas directors and executive officers in Melintas Schedule
14F-1
filed with the SEC on October 24, 2017, as supplemented on November 16, 2017.
Important Information and Where to Find It
Melinta will
file a proxy statement with the SEC in connection with the proposed transactions. The proxy statement will be sent to the stockholders of Melinta. Melinta stockholders are advised to read the proxy statement when it becomes available, because it
will contain important information about Melinta, and the proposed transactions. When filed, this document and other documents relating to the proposed transactions filed by Melinta can be obtained, free of charge, at the SECs website
(http://www.sec.gov), at the companys website (http://ir.melinta.com/), or by writing to the Secretary, Melinta Therapeutics, Inc., at
ir@melinta.com
.
This communication is being provided for informational purposes only and does not constitute (i) an offer to purchase, nor a solicitation of an offer to
sell, subscribe for or buy any securities, (ii) an offer to exchange any securities or (iii) the solicitation of any vote for approval of any transaction. There shall not be any offer, solicitation, sale or exchange of any securities in
any state or other jurisdiction in which such offer, solicitation, sale, or exchange is not permitted.
Item 9.01. Financial Statements and
Exhibits
(d) List of Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
Date: December 4, 2017
|
|
MELINTA THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
|
/s/ Paul Estrem
|
|
|
|
|
Paul Estrem, Executive Vice President, Chief
Financial Officer and Secretary
|
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From May 2024 to Jun 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Jun 2023 to Jun 2024